Please assess the completion status of the following clinical trial:

Trial Title: PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 with a hematological malignancy~* Informed consent~* Thrombocytopenia with untransfused platelet counts \< 20 x 10⁹/L in the out-patient or in the in-patient setting and one of the following criteria:~  * Acute thrombocytopenia in patients with hematological malignancies who are in remission and are receiving myelosuppressive consolidation chemotherapy that is expected to induce marrow aplasia for at least 2 weeks; or~ * Acute or chronic thrombocytopenia in patients with acute leukemia (myeloblastic or lymphoblastic) receiving induction or re-induction chemotherapy that is expected to induce marrow aplasia for at least 2 weeks; or~ * Expected chronic thrombocytopenia in patients with newly diagnosed marrow failure syndromes, myelodysplastic syndromes, aplastic anemia, chronic myelomonocytic leukemia or myelofibrosis; or~ * Expected chronic thrombocytopenia in patients with relapsed or refractory hematological malignancies; or~ * Hematopoietic stem cell transplant recipients with chronic thrombocytopenia due to chronic graft-versus-host disease (GVHD) or other causes~Exclusion Criteria:~* Acute promyelocytic leukemia~* Patient receiving anticoagulation~* Patient receiving antiplatelet agents~* Patient treated with antifibrinolytic agents (including EACA) within 14 days prior to screening~* Subjects receiving procoagulant agent including DDAVP, recombinant factor VII or prothrombin complex concentrate within 24 hours of enrollment~* Subject with known congenital bleeding disorders or platelet dysfunction~* Disseminated intravascular coagulation~* Fibrinogen level \< 150 mg/dl~* Patients with known lupus anticoagulant or positive antiphospholipid antibody~* History of arterial or venous thromboembolic disease 6 months prior to screening~* Patient requiring platelet transfusion threshold of \> 20 x 10⁹/L~* Active grade ≥ 2 bleeding at the time of randomization, including hematuria~* History of grade 4 bleeding~* Hematopoietic stem cell transplant recipient within 100 days post-transplant~* Pregnancy~* Known allergy to EACA~* History of veno-occlusive disease of the liver~* Myocardial infarction 6 months prior to screening~* Unstable angina~* Grade 2 renal dysfunction: creatinine \> 2-3 times the upper limit of normal

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prophylactic EACA (Type: EXPERIMENTAL): Prophylactic EACA 1000 mg PO twice daily if platelets \< 20 x 10⁹/L
- Platelet transfusion (Type: ACTIVE_COMPARATOR): Platelet transfusion if platelet count is \< 20 x 10⁹/L in the outpatient or \< 10 x 10⁹/L in the inpatient setting

Based on this trial design, predict the completion outcome and termination type (if applicable).